例如，1月6日，广州金域医学检验集团股份有限公司发布的公告显示，为增强投资者回报，促进全体股 东共享公司经营发展成果，提升投资者获得感，切实保护广大投资者利益等，公司拟实施2025年前三季 度分红，拟向全体股东每10股派发现金红利8.8元（含税）。同日，陕西斯瑞新材料股份有限公司也披 露前三季度分红方案，拟向全体股东每10股派发现金红利0.40元（含税）。 本报记者 桂小笋 2026年伊始，A股市场迎来了一波"分红暖意"。1月份以来，多家A股上市公司发布2025年前三季度利润 分配预案，以真金白银向投资者传递发展信心。预案的推出进一步凸显了分红制度化、常态化、高频次 的发展趋势，成为新年资本市场的亮点。 深圳市前海排排网基金销售有限责任公司研究员张鹏远告诉《证券日报》记者，上市公司在此时推出 2025年前三季度分红预案，具有多重积极意义。首先，政策层面鼓励提高分红频次，此举符合监管导 向。其次，春节前实施分红能够提升投资者获得感，彰显公司现金流稳健与回报诚意，增强市场信心。 再次，选择年报披露前的窗口期进行分红，可以避免与年度分红叠加，降低公司资金压力，同时提前稳 定股东预期，适配长期资金配置节奏。这种安排既 ...

人民财讯1月6日电，据迪安诊断（300244）消息，近日，广西壮族自治区科技厅正式公布"2026年第一 批广西科技计划拟立项项目名单"，迪安诊断子公司广西迪安与南宁市第四人民医院、广东省人民医院 联合申报的"赋能"行动计划重点研发课题《磁性荧光免疫层析检测平台用于百日咳等呼吸道感染快速诊 断的研究》成功获批。项目团队将联合多家科研机构，围绕磁性荧光免疫层析检测技术在百日咳等呼吸 道感染快速诊断中的应用，开展技术攻关，致力于突破现有技术瓶颈，构建更快速、更精准、易推广的 检测方案，助力实现临床早期精准诊断与防控。 ...

□ 本报记者 王梦然 12月18日，海南自由贸易港全岛封关运作正式启动。当天上午，南京江北新区生物医药谷会议室内，江 苏鼎泰药物研究(集团)股份有限公司工作人员正通过视频系统与海南文昌基地的团队连线。屏幕上实时 显示着实验猴舍内的画面，食蟹猴灵活地攀爬、跳跃，表现出高度的活力。"我们早在3年前就布局海 南，封关后，我们的实验动物进出口将享受更多便利。"工作人员指着屏幕说，今后全球研发合作通道 将更加顺畅。 业内认为，海南封关为江苏制造提供了一个"境内关外"的战略跳板，江苏企业可以依托海南，实现"全 球采购、国际加工、离岸销售"的新型商业模式，这不仅仅是成本节约，更是全球资源配置能力的跃 升。从制造业的"借船出海"，到生物医药的"研发+转化"，再到数字经济的"规则共建"……江苏将凭借 雄厚的产业基础和创新实力，成为这场改革中活跃的参与者与受益者。 巧借政策跳板，便利制造出海 鼎泰药研（集团）是这一模式的先行者。早在2022年，这家总部位于南京江北新区的CRO企业就开始 在海南文昌布局。"我们用时一年，建成了海南亚灵生物科技有限公司，并持续引进高质种群，公司拥 有国内规模最大的非人灵长类动物(NHP)研究核心年轻 ...

Core Insights - The integration of AI in medical testing is essential for improving healthcare efficiency and quality, as emphasized by experts at the Greater Bay Area Medical AI Conference [1] - The medical testing industry is undergoing a transformation driven by the deep integration of AI technology, shifting from traditional models to AI-enhanced solutions [1][2] Policy and Market Dynamics - National strategies like the "Healthy China 2030" plan provide a clear direction for the development of AI in medical testing, facilitating its commercialization through policy support [2] - The uneven distribution of medical resources in China creates a significant demand for AI solutions in medical testing, particularly in grassroots healthcare institutions [2] Disease Prevention and Healthcare Demand - There is an urgent need for early diagnosis and treatment of prevalent diseases, with AI significantly improving early screening efficiency and accuracy [3] - The rising health awareness among residents is driving demand for personalized and precise medical services, which traditional testing methods cannot adequately meet [3] Industry Ecosystem Transformation - The medical testing AI ecosystem is evolving, with upstream AI algorithm providers and downstream healthcare institutions collaborating to enhance service delivery [3][4] - The competitive landscape is shifting from isolated competition to an ecosystem-based approach, where collaboration among various stakeholders is key [4] Competitive Landscape and Growth Potential - The medical testing AI sector is one of the fastest-growing segments in the health industry, with projections indicating a market size exceeding 30 billion by 2027 [5][6] - The entry barriers in this sector are rising, with data quality, technological advancement, and compliance becoming critical factors for success [5] Company-Specific Advantages - Company has accumulated over 30 billion tests and nearly 30PB of medical data, providing a robust foundation for AI model training [6] - The company’s AI models are integrated into numerous healthcare institutions, demonstrating a strong connection between technology and practical application [6][7] Innovation and Compliance - The company is focusing on developing specialized AI models in collaboration with clinical experts, ensuring compliance and enhancing diagnostic capabilities [7] - The approach emphasizes transforming expert knowledge into scalable AI services, fostering a collaborative ecosystem across the healthcare value chain [7]

Core Insights - The establishment of Chongqing Liangjiang Xingkang Medical Equipment Co., Ltd. and the Di'an Southwest Digital Precision Center marks a significant development in the precision medicine sector in Chongqing [1][3] - The collaboration between Di'an Diagnostics and Liangjiang Xinshi Company aims to enhance diagnostic capabilities and expand services in the region [3] Group 1: Company Overview - Liangjiang Xingkang Company is a joint venture established by Di'an Diagnostics from Zhejiang and Liangjiang Xinshi Company [3] - Di'an Diagnostics is recognized as one of the early players in precision diagnostics in China, focusing on molecular diagnostics, pathology diagnostics, and mass spectrometry diagnostics [3] Group 2: Strategic Initiatives - The company plans to upgrade and build a digital regional medical testing center, relying on public hospitals in the area [3] - It will create a centralized procurement platform for medical reagents, consumables, and equipment, while also offering quality system construction, business training, technical support, and talent and research support [3] Group 3: Impact on the Industry - The Di'an Southwest Digital Precision Center aims to serve as a headquarters for precision medicine in the western region, integrating high-quality resources from industry, academia, and research [3] - The initiative will enhance diagnostic technology levels and promote the application of precision medicine in clinical settings, enriching the ecosystem of the biomedicine and medical device industries in Liangjiang New Area [3]

Core Viewpoint - The acquisition of a 40% stake in Huaxi Kangshengda by Wuhan Kangshengda is a strategic move to enhance the company's control over its operations and align with its overall business strategy in the southwestern region of China [1][2]. Group 1: Transaction Details - Wuhan Kangshengda successfully acquired a 40% stake in Huaxi Kangshengda from Huaxi Health Technology for a consideration of RMB 12.396 million [1]. - Following the completion of this transaction, Huaxi Kangshengda will become an indirect wholly-owned subsidiary of the company [2]. Group 2: Strategic Importance - Huaxi Kangshengda serves as a core platform for the company's "national special inspection network + regional center laboratory" strategy in the southwestern region, providing high-end special inspection services across Sichuan, Chongqing, Yunnan, and Guizhou [2]. - The full ownership will enhance the company's management and strategic direction over Huaxi Kangshengda, ensuring efficient execution of the overall strategy in the southwestern region [2]. - As a leading third-party medical testing (ICL) platform, Huaxi Kangshengda will support the company's dual-track development strategy of "ICL + IVD," promoting synergy between ICL-driven IVD product development and IVD service upgrades [2].

11月14日，《自然》杂志官网公布"2024自然指数-科研城市"排名，广州首次跃居全球第六 20日，广东省科学技术奖公布，广州再创佳绩，占全省获奖总数的65.6% 21日，2025年中国科学院、中国工程院院士增选结果正式揭晓，曾木圣、陈新、杨中民、徐瑞华、黄险波5位广州科学家入选，占全省5/9 近日，广州科创佳报频传。 亮眼成绩背后，是广州多年来以人才为科技创新发展核心，在创新链上勇于投入、默默耕耘的"开花结果"。有人于实验室坚 守，点亮"从0到1"的原创星火；有人进行概念验证，让"从1到10"的雏形淬火成器；有人奔赴产线，促成产业"从10到100"的百花齐放。人才之潮，百川赴 海；金融之风，鼓帆助航；创新之轮，飞旋疾驰。如今，广州结下累累科创硕果，正似木棉欲燃，照彻南天。 企业造"士" 创新主体地位不断凸显 当前， 广州的科技企业数量已达1.35万家，比2015年翻了7倍。 企业是科技创新的主体，科技企业已成为我国引领科技创新和产业创新的主导力量，同时 也成为培养科技人才的主战场。 新晋5位两院院士中， 黄险波院士的身份十分显眼，他担任金发科技股份有限公司首席技术官、高分子材料资源高质化利用国家重点实验室主 ...

Core Viewpoint - The article highlights the financial struggles faced by medical testing companies in China, particularly due to increased accounts receivable and the impact of the COVID-19 pandemic on cash flow and profitability [2][4]. Group 1: Legal and Financial Issues - Capbio (300639.SZ) has disclosed a lawsuit regarding overdue payments, with claims amounting to 357 million yuan related to unpaid goods and services from 2020 to 2022 [2]. - A total of seven medical testing companies in the A-share market reported net losses attributable to shareholders in the first three quarters of this year, with six of them expected to continue facing losses in 2024 [3]. Group 2: Profitability Decline - Dean Diagnostics (300244.SZ) reported a net profit of 56.70 million yuan for the first three quarters, a decline of 56.67% year-on-year, attributed to price reductions in testing services [4]. - Gold Domain Medical (金域医学) recorded a provision for asset impairment of 345 million yuan, primarily due to accounts receivable impairment losses, significantly impacting its consolidated profit [5]. Group 3: Accounts Receivable Management - Medical testing companies are experiencing longer collection periods from public hospitals, leading to increased credit impairment [7]. - Recent government debt reduction policies have reportedly accelerated the collection of accounts receivable from public hospitals, particularly noted in the third quarter [7]. - Companies like Dean Diagnostics and Puni Testing are implementing stricter accounts receivable management strategies, including tailored collection plans for major clients [8].

Core Insights - The medical testing industry is facing significant challenges due to increased accounts receivable and declining profits, particularly following the COVID-19 pandemic [1][4][5] Group 1: Accounts Receivable and Financial Performance - Four companies have accounts receivable exceeding 2 billion yuan, with Capbio (凯普生物) involved in lawsuits to recover 357 million yuan in overdue payments [1] - In the first three quarters of this year, at least seven medical testing companies reported net losses attributable to shareholders, with six of them expected to continue this trend into 2024 [1] - Specific losses reported include: Puni Testing (谱尼测试) at 199 million yuan, RunDa Medical (润达医疗) at 163 million yuan, and Capbio at 128 million yuan [1] Group 2: Impact of Price Reductions and Impairment Provisions - Price reductions in the testing sector have led to widespread profit shrinkage among medical testing companies, with some firms making impairment provisions for accounts receivable [4] - Companies like KingMed Diagnostics (金域医学) have made significant impairment provisions, totaling 345 million yuan, primarily for accounts receivable, which reduced their consolidated profit by the same amount [4] - Lanwei Medical (兰卫医学) reported a total impairment provision of 16.73 million yuan, with 13.50 million yuan specifically for accounts receivable [5] Group 3: Recovery Trends and Future Outlook - The Ministry of Finance has indicated a commitment to debt reduction policies, which may accelerate the collection of accounts receivable from public hospitals [5] - Companies are implementing strategies to manage accounts receivable more effectively, with Puni Testing focusing on tailored collection strategies for major clients [6] - DiAn Diagnostics (迪安诊断) anticipates improved collection trends in the second half of the year, with expectations that all COVID-related accounts receivable will be fully provisioned by year-end [5][6]

Core Viewpoint - Eddiecon Holdings (09860) announced the acquisition of 100% of the issued shares of Crown Bioscience International for a total purchase price of $204 million, which aligns with the company's strategy to expand its product portfolio and is expected to bring long-term strategic benefits [1][2]. Group 1: Acquisition Details - The buyer, Miramar Lifesciences Limited, a wholly-owned subsidiary of Eddiecon, entered into a share purchase agreement with the seller, JSR Life Sciences, LLC, regarding the acquisition of the target company [1]. - Upon completion of the transaction, Crown Bioscience International will become a wholly-owned subsidiary of Miramar Lifesciences Limited [1]. - The target company is a global Contract Research Organization (CRO) focused on advancing precision medicine in oncology, immuno-oncology, and other therapeutic areas [1]. Group 2: Company Operations - Eddiecon primarily provides Integrated Clinical Laboratory (ICL) services, along with medical testing, clinical trials, research services, health management, and pathology consultation services [1]. - The company focuses on research and development in core disease areas such as infectious diseases, women's health, solid tumors, perinatal and pediatric care, and hematology, covering multiple disciplines including internal medicine, pediatrics, obstetrics and gynecology, oncology, and neurology [1].